O Glimaday-Forte 1 Tablet PR contains a combination of Glimepiride 1mg and Metformin 1000mg, formulated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The combination of these two agents offers complementary mechanisms of action, resulting in effective reduction of blood glucose levels. O Glimaday-Forte 1 Tablet PR is indicated for patients inadequately controlled on diet and exercise alone or those who require dual therapy to achieve optimal glycemic targets. It is particularly useful in patients where monotherapy with either agent is insufficient. The prolonged-release formulation ensures a steady release of active ingredients, promoting better compliance and minimizing gastrointestinal side effects commonly associated with Metformin. Patients should adhere to prescribed dosage and lifestyle modifications, including diet and exercise, to maximize therapeutic outcomes. Regular monitoring of blood glucose levels, renal function, and potential adverse effects such as hypoglycemia or lactic acidosis is recommended. This medication should be used under medical supervision, with caution in patients with renal impairment, hepatic dysfunction, or cardiovascular disease.